Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03350620 · ClinicalTrials.gov registry record · Phase 3
CHAMP: Study of NVK-002 in Children With Myopia
A Phase 3 study of Myopia, sponsored by Vyluma.
- Completed
- Registry status
- Phase 3
- Development phase
- 670
- Enrollment target
- 20
- Study locations
NCT03350620 is a Phase 3 study of Myopia that has completed, run by Vyluma. The registered enrollment target is 670 participants, above the 261-participant average among 90 other Myopia trials with a reported enrollment target (157% higher). The trial reports 20 study locations across 16 states.
The verdict
NCT03350620, a Phase 3 study of Myopia, has completed, sponsored by Vyluma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 670 participants
- Enrollment target
- 20
- Study locations
Study Summary
Stage 1: To evaluate the safety and efficacy of 2 concentrations of NVK-002 compared to Vehicle (placebo) for slowing the progression of myopia in children over a 3 year treatment period. Stage 2: To observe safety and efficacy in subjects re-randomized to one (1) year of treatment with NVK-002 or Vehicle following 3 years of treatment in children with progressive myopia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NVK-002 Concentration 1
- DRUG NVK-002 Concentration 2
Study Locations (20)
California
- Site #015 - Berkeley
- Site #003 - Fullerton
- Site #016 - San Diego
Pennsylvania
- Site #011 - Elkins Park
- Site #017 - Lancaster
Washington
- Site #012 - Kirkland
- Site #020 - Spokane
Arizona
- Site #009 - Tucson
Connecticut
- Site #005 - Danbury
Florida
- Site #004 - Maitland
Illinois
- Site #024 - Peoria
Massachusetts
- Site #006 - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 670 participants |
| Start Date | 2017-11-20 |
| Est. Completion | 2023-10-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03350620
The ClinicalTrials.gov registry entry for NCT03350620 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 670 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 261-participant average among 90 other Myopia trials with a reported enrollment target (157% higher). The listed sponsor is Vyluma, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myopia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03350620 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Pennsylvania, Washington.
Frequently Asked Questions
What is clinical trial NCT03350620 about?
NCT03350620 is a clinical study titled "CHAMP: Study of NVK-002 in Children With Myopia". Stage 1: To evaluate the safety and efficacy of 2 concentrations of NVK-002 compared to Vehicle (placebo) for slowing the progression of myopia in children over a 3 year treatment period. Stage 2: To observe safety and efficacy in subjects re-randomized to one (1) year of treatment with NVK-002 or ...
What is the current status of trial NCT03350620?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 670 participants. The study started on 2017-11-20. Estimated completion is 2023-10-19.
What conditions does trial NCT03350620 study?
This clinical trial studies the following conditions: Myopia.
What interventions are being tested in trial NCT03350620?
The interventions under investigation include: Placebo (DRUG), NVK-002 Concentration 1 (DRUG), NVK-002 Concentration 2 (DRUG).
Who is sponsoring clinical trial NCT03350620?
This trial is sponsored by Vyluma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03350620 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Clinical Evaluation of WaveLight Plus LASIK
RECRUITING
-
Violet Light for the Suppression of Myopia
RECRUITING · NA
-
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.